- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared with first-generation ...
With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights Veradigm’s Clinical ...
The generation of synthetic data in healthcare has emerged as a promising solution to surmount longstanding challenges inherent in the use of real patient data. By replicating the underlying ...
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses ...
Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...
Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular BIRMINGHAM, AL, UNITED STATES, January 8, 2026 ...
BioNTech will present significant clinical trial data at the prestigious ASCO Annual Meeting, highlighting the advancement of its diversified oncology portfolio. The preliminary results for BNT327 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results